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Background/Aim: Cisplatin is a highly effective chemotherapeutic agent used in the treatment of solid organ cancers. Besides its
chemotherapeutic effectiveness, cisplatin administration is associated with numerous side effects. Of those, the most clinically significant
and common effect is nephrotoxicity. Recent studies reported that oxidative stress and inflammation are probably the most important
mechanisms that contribute to the nephrotoxicity. N-acetylcysteine (NAC) is an antioxidant and antiinflammatory agent. In the present
study, the effects of NAC on cisplatin-induced nephrotoxicity were investigated.
Materials and methods: Rats were divided into four groups each including eight rats: CONT, NAC-250, CP, and CP+NAC. Rats in
experimental groups were treated intraperitoneally (i.p.) with a single dose of cisplatin (10 mg/kg body weight) and i.p. with NAC (250
mg/kg body weight) for three consecutive days. Nephrotoxicity was determined by plasma BUN and creatinine levels. In tissue samples,
myeloperoxidase (MPO), nuclear factor-kappa B (NF-kB), high mobility group box-1 (HMGB-1), total oxidant status (TOS), and total
antioxidant status (TAS) levels were measured. Kidneys were analyzed histopathologically as well.
Results: It was revealed that cisplatin was not effective on MPO, HMGB-1 and NF-kB levels but did increase TOS levels and decrease
TAS levels in tissue samples. Interestingly, NAC elevated MPO and HMGB-1 levels significantly. Nevertheless, NAC ameliorated
histological and functional changes in kidney tissues.
Conclusion: It is suggested that inflammation has a limited effect on cisplatin nephrotoxicity in this experimental design, and, as
reflected by decreased BUN and creatinine levels, NAC can be used as an additional therapeutic agent in standard cisplatin treatment
protocols.
Key words: Rats, cisplatin, oxidative stress, inflammation, N-acetylcysteine

1. Introduction
Cisplatin is one of the most effective chemotherapeutic
agents used for the treatment of solid tumors. Despite its
antitumor activity, it is also known for serious side effects.
Major side effects include nephrotoxicity, neurotoxicity,
and myelosuppression, and among these, the most serious
and dose-limiting side effect that limits its clinical use
and anticancer activity is nephrotoxicity. Despite its toxic
characteristics, it is still widely used thanks to its therapeutic
efficacy considering its risk/benefit ratio [1].
While cisplatin interacts with many cell components, the
main biological target of the drug is deoxyribonucleic acid
(DNA) [2]. However, as proximal tubule cells are nondividing
cells, the nephrotoxic effect is believed to occur via mechanisms

other than DNA damage. While different mechanisms are
suggested for the development of nephrotoxicity, the most
commonly accepted and investigated mechanisms are
apoptosis, oxidative stress, and inflammation [3].
As no approved treatment protocol or specific antidote to
be used against possible toxic effects of cisplatin use currently
exists [4], different toxicity-preventing strategies are being
rigorously investigated today.
Routine applications to prevent nephrotoxicity include
creating forced diuresis using mannitol and furosemide, using
hypertonic chlorine solutions, using alternative cisplatin
regimens, avoiding combination with other nephrotoxic
agents, and using it together with compounds thought to be
able to prevent nephrotoxicity [5].
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Despite intense prophylactic attempts, nephrotoxicity
has been reported even in 20%–30% of patients who
received a single dose of cisplatin [1]. As renal toxicity is
accepted to be cumulative, it is suggested that successive
use of cisplatin would increase the incidence and severity
of toxicity [6]. However, despite the accepted opinion,
platin levels in the renal tissues of patients who died during
cisplatin treatment have been demonstrated to be based on
the last treatment dose right before dying and not on the
total dose the patient received [7]. Therefore, additional
measures might be necessary to take precautions against
the development of nephrotoxicity even in patients who
use a single dose of cisplatin.
Being the acetylated precursor of L-cysteine,
N-acetylcysteine (NAC) has been used for a long time as a
mucolytic agent, and in conditions such as acetaminophen
intoxication, doxorubicin-induced cardiotoxicity, stable
angina pectoris, acute respiratory distress syndrome, and
psychiatric disorders. Moreover, it has a very low toxicity
level [8]. Being oxidized by various radicals and also acting
as a nucleophile, NAC, thanks to these characteristics,
can reduce the disulfide bridges in proteins, act as a
free-radical capturer, and produce metal chelation [9].
Furthermore, NAC is also known for its antiinflammatory
and antiapoptotic properties [10]. In addition to these
direct effects, NAC also exerts its effect by increasing GSH
levels [8,9].
This study investigated the contribution of
oxidative stress and inflammation to cisplatin-induced
nephrotoxicity, and also the association of NAC with
these mechanisms and whether it is protective against
nephrotoxicity in a rat model.
2. Materials and methods
The study was approved by the Erciyes University Local
Ethics Committee for Animal Experiments (Ethics
Committee No: 13/150). The experiments were performed
in the Erciyes University Experimental Research and
Application Center Laboratory.
2.1. Animals
Male Wistar albino rats (n = 32) 6–8 months old and
weighing 280–445 g were housed under controlled
standard environmental conditions of temperature (22
±3 °C) and light (12/12-h light/dark cycle). Food and
water were provided ad libitum. All the procedures were
performed in compliance with the Helsinki Declaration
and International Guiding Principles for Biomedical
Research Involving Animals.
2.2. Experimental design
All rats planned to be used in the experiment were
weighed and experimental groups were formed in such a
way that the groups were not different from each other.
After a 1-week acclimation period, animals were randomly
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divided into four groups (8 animals in each group): the
control, cisplatin (CP), NAC (NAC-250), and cisplatin
plus NAC (Cp+NAC) groups. The CP group was treated
with a single intraperitoneal (i.p.) injection of 10 mg/kg
rat body weight of cisplatin (Cisplatin DBL, 100 mg/100
mL), whereas the control group was injected with saline
(1 mL/kg). The NAC-250 group was treated with i.p.
administration of NAC (250 mg/kg; Asist, Bilim 300
mg/3 mL, 10%), while the Cp+NAC group was treated
with a single dose of cisplatin (10 mg/kg, i.p.) and three
consecutive days of NAC (250 mg/kg, i.p.) (Table 1).
The animals in the last group were administrated NAC 4
hours after the cisplatin injection to avoid cisplatin–NAC
interactions [11].
Before and after the experiment, animals were housed
separately in metabolic cages. For each animal, 24-h urine
samples were collected and total volume was recorded.
Samples from the collected urine were centrifuged for
15 min at 1000 × g and 4 °C and then kept frozen until
analyzed for estimation of urea nitrogen, creatinine, and
microalbumin. The body weight of each rat was recorded
on the first and last days of the experimental period for
calculation of change in body weight.
At the end of the experiment, rats were anaesthetized
with i.p. injection of 80 mg/kg ketamine (Ketalar flacon;
Pfizer, USA) and 10 mg/kg xylazine (Rompun; Bayer,
Germany). After dissection, blood samples were taken
from the abdominal aorta and kidneys were rapidly
excised and trimmed of connecting tissue. The left kidneys
were washed free of blood with ice-cold 0.9% NaCl
solution and they were then blotted and finally kept at
–40 °C until use in biochemical analyses. For histological
analysis, right kidneys were put immediately in 10%
neutral formaldehyde.
2.3. Biochemical analysis
Plasma and urine urea nitrogen and creatinine assays were
performed photometrically on a Roche/Hitachi cobas
c501 system (Roche Diagnostics, USA).
For tissue analysis, weighed kidney samples were
homogenized in ice with 0.015 M phosphate buffer (pH
7.5) in a ratio of 1:4. They were then centrifuged at 4 °C
and 20,000 × g for 15 min. The supernatant was used for
total oxidant capacity (TOC), total antioxidant capacity
(TAC), myeloperoxidase (MPO), high mobility group
box-1 (HMGB-1), and nuclear factor kappa B (NF-kB)
analysis.
TOS (RL0024) and TAS (RL0017) were evaluated
photometrically in rat renal tissues supernatants with
available commercial assay kits (Rel Assay Diagnostics,
Turkey).
In rat kidney tissues, MPO (Cat No: 201-11-0575),
NF-kB (Cat No: 201-11-0288), and HMGB-1 (Cat No:
201-11-0258) levels were measured according to the
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manufacturer’s instructions using commercially available
ELISA kits (Sunred Biological Technology Co., China).
Tissue biochemical parameter results were obtained by
proportioning to protein values calculated by the Lowry
method [12] in the same tissues.

two dependent groups. One-way analysis of variance
(ANOVA) was used to assess the effect of NAC treatment
on biochemical parameters, urine volume, and rat body
weight. If statistically significant differences were found
for the groups, the data were further analyzed using the
Tukey multiple comparison test. The differences among the
groups were evaluated by using the Kruskal–Wallis test for
histological parameters and the comparisons between every
two groups were made using the Mann–Whitney U test.
Data were considered statistically significant at P < 0.05.
3. Results
While there was no difference between the CONT and
NAC-250 groups in terms of poststudy plasma BUN and
creatinine levels, a significant increase was present in the
CP and CP+NAC groups compared to the CONT and
NAC-250 groups. Again, in terms of those two parameters,
a significant decrease was observed in CP+NAC group
compared to the CP group (Table 3).
As seen in Table 4, no significant difference was observed
between the prestudy urine volumes of the groups. When
intragroup pre- and poststudy values were compared, an
increase was observed in the urine volumes of all groups
except for NAC-250. In the intergroup comparison at
the end of the study, urine volume was only increased in
the CP+NAC group compared to the control group; no
difference was observed in the CP and CP+NAC groups,
and urine volume was significantly higher in the CP and
CP+NAC groups compared to the NAC-250 group. For
microalbumin levels, no difference was observed between
the groups in terms of both pre- and poststudy values, and in
intragroup comparisons, a significant increase was observed
in the CP group compared to the prestudy value (Table 4).

2.4. Histological evaluation
For light microscopic evaluations, the kidney samples were
fixed in 10% buffered formalin for 48 h and processed for
routine paraffin embedding. For general morphological
evaluation, approximately 5-µm-thick sections were
stained with hematoxylin and eosin (H&E). All of the
stained sections were observed and photographed with
a digital camera (Olympus C-5060; Olympus, Japan)
attached to a photomicroscope (Olympus BX51; Olympus,
Japan).
The microscopic scoring of the right kidneys was
carried out in a blinded fashion by a histologist who was
unaware of the treatment groups and assigned a score
that represented the approximate extent of hemorrhage,
tubular epithelial cell damage, and necrosis according to
Abdelrahman et al. [13]. These parameters were evaluated
on a scale of 0–3, which ranged from absent (0) and mild
(1) to moderate (2) and severe (3) (Table 2).
2.5. Statistical analysis
Statistical analysis of the study data was performed with
IBM SPSS Statistics version 23 software. Conformity of
the variables to normal distribution was assessed with the
Shapiro–Wilks test. Statistical data were stated as mean
± standard deviation (SD) or median and interquartile
range for normally and nonnormally distributed variables,
respectively. A paired t-test was used to compare
Table 1. Experimental design.
Group

n

Agent (i.p.)

CONT

8

1 mL/kg* saline

CP

8

10 mg/kg* cisplatin

NAC-250

8

250 mg/kg* N-acetylcysteine

CP+NAC

8

10 mg/kg* cisplatin + 4 h later and 2 consecutive days 250 mg/kg* N-acetylcysteine

*: Rat body weight; n: number of rats in each group; CONT: control group; CP: cisplatin group; NAC-250: N-acetylcysteine
group; CP+NAC: cisplatin plus N-acetylcysteine group; i.p.: intraperitoneal.
Table 2. Histological scoring table.
Absent

Mild

Moderate

Severe

Hemorrhage

0

1

2

3

Tubular epithelial cell damage

0

1

2

3

Necrosis

0

1

2

3
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Table 3. Poststudy BUN and plasma creatinine levels of the rats.
Groups
CONT
(n = 8)

NAC-250
(n = 8)

CP
(n = 8)

CP+NAC
(n = 8)

P

Mean ± SD
BUN (mg/dL)

18.77 ±1.90

16.09± 2.10

137.09 ± 33.82 102.4±4.67

0.001

Creatinine (mg/dL)

0.44 ± 0.08

0.38 ± 0.04

3.59 ± 1.01

0.001

1.87 ± 0.20

P: P-value for the measurements after the experiments among the four groups.

Table 4. Pre- and poststudy 24-h urine volumes and microalbumin levels of the rats.
Groups
CONT
(n = 8)

NAC-250
(n = 8)

CP
(n = 8)

CP+NAC
(n = 8)

Significance

P1: 0.301
P2: 0.001

Mean ± SD
Urine volume (mL)
Before
After

6.17 ± 2.05
9.89 ± 3.17

8.24 ± 2.08
7.37 ± 1.23

6.79 ± 2.89
14.34 ± 5.43

6.65 ± 1.70
20.47 ± 6.84

P*

0.028

0.238

0.002

0.001

Microalbumin (mg/dL)
Before
After

3.47 ± 2.08
3.80 ± 2.08

2.98 ± 1.69
5.00 ± 2.68

1.87 ± 1.56
5.97 ± 4.50

2.97 ± 1.60
5.59 ± 3.73

P*

0.675

0.053

0.040

0.104

P1: 0.330
P2: 0.602

P1: P-value for basal measurements among the four groups. P2: P-value for the measurements after experiments among
the four groups. P*: P-value for before and after measurements for each group.

No difference was observed for the prestudy body
weights of the rats; however, a statistically significant
decrease was observed in all groups at the end of the study.
While no significant difference was observed between the
groups at the end of the study, when percentage changes
were compared between the groups, the weight loss that
was not observed in the control group and NAC group
was observed in both groups receiving cisplatin (CP and
CP+NAC groups). On the other hand, no difference was
observed for % change in the CP+NAC group compared
to the CP group (Table 5).
Tissue MPO and HMGB-1 values were significantly
increased only in the NAC-250 group compared to the
CONT group and there was a numerical increase in NF-kB
levels. Compared with the NAC-250 group, a significant
decrease was observed in the MPO, HMGB-1, NF-kB, and
TAS levels of the CP and CP+NAC groups; no significant
difference was observed between the groups that received
cisplatin alone or combined with NAC. TOS levels were
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observed to increase with cisplatin use; however, they
could not be decreased by NAC administration (Table 6).
When renal tissue was assessed for hemorrhage,
tubule cell damage, and tubular necrosis, no difference
was observed between the CONT and NAC-250 groups
and a significant increase was observed in the CP group
compared to the CONT and NAC-250 groups. Hemorrhage
and necrosis improvement was observed in the CP+NAC
group but there was no difference compared to the control
group. When assessed for tubule cell damage, while there
was still difference compared to the CONT and NAC250 groups, significant improvement was observed in the
CP+NAC group compared to the CP group (Table 7).
Histopathologically, the saline-administrated rats
had normal kidney architecture. In the CP group, the
kidneys were generally worn and had a morphological
appearance that had lost its natural color and showed
significant hemorrhage, necrosis, and tubule cell damage.
Vacuolization of tubular cells and brushed edge loss in
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Table 5. Change in the body weights of the rats in the study group.
Groups
CONT
(n = 8)

NAC-250
(n = 8)

CP
(n = 8)

CP+NAC
(n = 8)

P

0.877
0.067
0.001

Mean ± SD
Rat body weights (g)
Before
After
% Change

363.14 ± 60.98
353.5 ± 54.81
2.45 ± 1.72

353.63 ± 24.38
348.0 ± 21.29
1.54 ± 1.35

357.54 ± 28.24
308.97 ± 21.24
13.44 ± 3.88

370.69 ± 51.08
317.55 ± 43.69
14.32 ± 1.75

P*

0.007

0.018

0.001

0.001

P: P-value among the four groups. P*: P-value for before and after measurements for each group.

Table 6. Changes in the oxidative stress and inflammatory parameters of the rats in the study groups.
Groups
CONT
(n = 8)

NAC-250
(n = 8)

CP
(n = 8)

CP+NAC
(n = 8)

P

Mean ± SD
MPO
(ng/mg protein)

1.12 ± 0.29

1.64 ± 0.32

0.82 ± 0.20

0.84 ± 0.18

NF-κB
(ng/mg protein)

0.46 ± 0.05

0.56 ± 0.09

0.35 ± 0.05

0.40 ± 0.14

HMGB-1
(ng/mg protein)

0.58 ± 0.16

0.82 ± 0.20

0.44 ± 0.11

0.47 ± 0.06

TAS ((mmol Trolox equiv./g protein)

0.024 ± 0.003

0.025 ± 0.003

0.017 ± 0.002

0.016 ± 0.003

0.001

TOS (µmol H2O2 equiv./g protein)

0.112 ± 0.012

0.122 ± 0.015

0.133 ± 0.016

0.136 ± 0.018

0.016

0.001
0.001
0.001

P: P-value among the four groups.

Table 7. Histological study results.
Groups
CONT
(n=8)

NAC-250
(n = 8)

CP
(n = 8)

CP+NAC
(n = 8)

P

Median (interquartile range)
Hemorrhage

0.0 (0.0–1.0)

0.5 (0.0–1.0)

3.0 (2.25–3.0)

1.5 (0.0–2.0)

0.001

Tubule epithelial cell damage

0.0 (0.0–1.0)

1.0 (0.25–0.1)

3.0 (2.0–3.0)

2.0 (2.0–2.0)

0.001

Tubular necrosis

0.0 (0.0–0.0)

0.0 (0.0–1.0)

2.0 (2.0–2.75)

0.0 (0.0–1.0)

0.001

P: P-value among the four groups.
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proximal tubules were observed. The NAC-250 group had
very mild hemorrhage, necrosis, and tubule cell damage.
In the CP+NAC group, hemorrhage and tubular epithelial
cell damage were observed similarly to the CP group, but
cells with necrosis were fewer in number (Figure).
4. Discussion
Cisplatin is one of the most potent chemotherapeutic
agents commonly used for the treatment of cancer [4].
Clinical use of cisplatin leads to successful results in the
treatment of many solid organ tumors including those of
the head, neck, lungs, testes, and ovaries [14]. However,
cisplatin and its derivatives also have side effects limiting
their use, including mainly nephrotoxicity, followed by
ototoxicity, cardiotoxicity, and myelosuppression [4].
Various agents with antioxidant properties such
as selenium, vitamin E, dimethyl thiourea (DMTU),

theophylline, amifostine, and NAC were used as
chemoprotectives for the prevention of cisplatininduced nephrotoxicity, and positive effects have been
demonstrated [15]. The only agent approved by the US
Food and Drug Administration for the prevention of
cisplatin nephrotoxicity in non-small-cell lung cancer
and advanced ovarian cancer is amifostine [16]. However,
the high cost, side effects, and negative effects on the
antitumor activity of cisplatin limit the use of amifostine
[17]. In addition to its chemical similarity to amifostine,
as an agent that is being used in clinical practice for many
years and is more cost-effective without serious side effects,
NAC [18] was chosen for this study.
The possibility of negative effects on anticancer efficacy
of the chemotherapeutic agent in use is one of the major
factors limiting the clinical use of a chemoprotective agent
[19]. Different studies have shown the advantages of the

Figure. Morphology of the kidney tissue. Images are representative of the H&E-stained sections of kidneys from the experimental
groups. CONT: Kidney tissue showing normal structure in control group; CP: cisplatin-injured kidney tissue obtained from the
cisplatin group; NAC-250: NAC-treated group; CP+NAC: kidney tissue obtained from the cisplatin + NAC treated group. Original
magnification: 40×, scale bar: 100 µm. Thick arrow (→): hemorrhage; arrowhead (<): interstitial edema; star (*): vacuolization.
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timing and/or the route of the administration to minimize
the interaction between the chemotherapeutic agent in use
and the chemoprotective agent, and maximize the benefits
of the chemoprotective agent [11,20,21].
Showing the nephroprotective effects obtained by NAC
on tumor chemotherapy together, Muldoon et al. showed
that NAC administered 4 h after cisplatin administration
had no negative effect on antitumoral activity [11].
Therefore, an interval of 4 h was observed between the
administrations of two agents.
The effects of NAC on cisplatin-induced renal toxicity
were evaluated via different pathways in the literature. It
has been demonstrated that it is possible to improve the
demonstrated parameters of cisplatin-induced weight loss
[11,13,22], apoptosis induction and caspase activation
[20,23], oxidative stress and inflammation [23,24], and
renal hemodynamic changes such as renal blood flow
and blood pressure [13] by NAC. Cisplatin-induced
acute renal injury can be described as acute renal failure
characterized by decreased renal blood flow, which also
aggravates the GFR decrease. As this hypofiltration is
usually closely associated with minimal tubular proteinuria
and elevated plasma BUN/ creatinine levels [1], these are
the parameters that are usually evaluated in studies on
cisplatin nephrotoxicity.
In this study, findings of significant hemorrhage,
necrosis, and tubule epithelial cell damage (vacuolization
in tubule cells, loss of brush border in proximal tubules),
which had a direct positive association with low urine and
high plasma BUN and creatinine levels in rats that received
cisplatin, proved the development of nephrotoxicity in
rats receiving cisplatin. Moreover, proteinuria, which
was assessed using microalbumin levels in this study, is
believed to be an important indicator of nephropathy.
Glomerular damage, which is especially seen at higher
doses, is implicated for the development of proteinuria
[14].
Consistent with this study, it has been suggested that
cisplatin administration combined with NAC at different
doses and times can decrease the levels of serum/plasma
BUN and creatinine levels [13,21,22,24]. In addition to the
demonstrated functional improvement, histopathological
improvement was also observed in this study and
different studies in the literature [13,24,25]. Even though
the rat species, the dose, and the method and timing of
administration of cisplatin and NAC were different in
those studies, comparable results were obtained, and this
is striking.
However, while BUN and creatinine levels were
significantly decreased compared to the CP group in this
study, they did not reach the levels of the control group.
The timing of NAC administration after cisplatin is also
believed to be a factor in this situation. Likewise, Muldoon

et al. also obtained comparable results with comparable
timing of administration [11].
The most common gastrointestinal side effects of
platin-containing chemotherapeutics such as cisplatin
include nausea, vomiting, diarrhea, constipation, and
oral mucositis. These side effects lead to rapid weight loss
secondary to malnutrition and dehydration in patients
[26]. While there are some studies in the literature showing
that there is no change in body weight in rats receiving
cisplatin [27,28], other studies generally reported decrease
in body weight [11,13,21,22]. Significant weight loss was
observed in all groups in this study whether receiving
or not receiving cisplatin. This might be explained by
rats staying in metabolic cages for a total of 2 days at the
beginning and end of the experiment and an impaired diet
due to this stay. In addition to this, weight loss observed
during the experiment in the groups receiving cisplatin
was determined to be approximately 14%, which was
considerable compared to the other groups. Metabolic
cage-induced lack of nutrition, which was common for all
groups, together with gastrointestinal toxicity-associated
modest diarrhea and tubular damage-induced severe
polyuria might explain the weight loss in rats receiving
cisplatin. However, contrary to the changes in biochemical
parameters, as the excessive weight loss observed with
cisplatin administration was close to the level observed in
the CP+NAC group, it can be said that at this dose and
timing, NAC cannot prevent the gastrointestinal toxicity
of cisplatin, which is believed to cause weight loss.
One of the outcomes of cisplatin-induced renal tubular
damage is severe polyuria [3]. While polyuria was shown
in this study and also in different studies in the literature
[29,30], there are also studies reporting the opposite
[13,31]. Abdelrahman et al. [13] reported that urine
output remained unchanged with cisplatin administration
and associated this entity with diarrhea-induced excessive
fluid loss and 95% decrease in CCr.
While it was shown that NAC does not have a polyuric
effect when the results of the NAC-alone group were
evaluated, a surprising increase in the 24-h urine volume
was observed in CP+NAC group compared to all other
groups, including the CP group. Similarly, Abdelrahman
et al. [13], who administered cisplatin and NAC together,
demonstrated a substantial numerical increase in their
CP+NAC group compared to the cisplatin group, though
the difference was not statistically significant. However,
this phenomenon could not be explained.
The etiology of cisplatin nephrotoxicity involves many
complicated and unclear factors and various signal pathways.
However, the main ones especially include SOR production
and antioxidant system dysfunction [24], and, accepted as
an extension of this, the inflammatory response mediated by
NF-kB, a prototypical proinflammatory agent [19].
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In support of the contribution of free radicals to
cisplatin-induced acute renal failure, Matsushima et al.
[32] demonstrated that DMTU and sodium benzoate,
which play a role as free-radical capturers, prevent
cisplatin-induced malondialdehyde (MDA) increase,
reduce the elevation in serum creatinine levels and NAG
excretion and thereby tubular damage formation, and
increase the regeneration of renal tubular cells. Moreover,
Shalby et al. [24] reported reduced total antioxidant
capacity in addition to high plasma/tissue MDA and NO
levels due to antioxidant system failure in rats receiving
cisplatin. This study showed that TOS levels in the renal
tissues were significantly increased and TAS levels were
decreased compared to the controls. On the other hand,
NAC administered together with cisplatin did not have any
significant effect on the cisplatin-induced TOS increase
and TAS decrease in the renal tissues. In this case, it can
be said that NAC is not used for its direct radical capture
effect, but rather for its beneficial effect of increasing GSH
concentrations, which was shown to be more effective in in
vivo conditions [9], which was demonstrated in this study
by the BUN and creatinine levels. However, the lack of the
expected increase in TAS levels might be due to molecular
interaction of high-dose cisplatin with GSH [33].
As it is known that cisplatin nephrotoxicity also involves
inflammation in addition to oxidative stress [16], it can be
said that the assessment of activity and/or concentration
of neutrophil-specific MPO would be important for the
diagnosis and monitorization of nephrotoxicity. Moreover,
it was demonstrated that MPO levels were significantly
higher, or in other words, neutrophil activation was
increased, in the animals receiving cisplatin compared to
the healthy animals [27,34].
However, a numerical decrease was observed in the
MPO levels as a result of cisplatin administration in
this study, though this was not statistically significant.
While neutrophil infiltration-mediated inflammation is
considered to be one of the possible causes of cisplatininduced nephrotoxicity, no improvement was reported
in the tubular necrosis and renal functions in mice with
cisplatin-induced acute renal failure, which received
the RB6-8C5 monoclonal antibody to create neutrophil
depletion in peripheral and renal tissues, even though
there was no neutrophil infiltration [35]. In other words, it
can be said that the inflammatory status caused by severe
cisplatin-induced renal toxicity as demonstrated by renal
functions and histological examination is not caused by
neutrophils.
Moreover, the fact that the inhibitory effect of cisplatin
on neutrophil activation has been demonstrated [36]
and renal platin accumulation has been demonstrated
in different studies in the literature [13,31], even though
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plasma/renal cisplatin levels were not assessed in the
present study, might suggest that the numerical decrease
in tissue MPO values might be due to the inhibitory effect
of cisplatin on neutrophil activation as a result of renal
tissue accumulation.
No study was found in the literature showing the
effect of NAC in combination with cisplatin on neutrophil
activation and/or MPO levels. Furthermore, MPO,
NADPH oxidase, and NF-kB p65 subunit activities in the
renal tissues of the rats receiving cisplatin together with
fisetin, which is a natural antioxidant and was shown
to increase GSH levels, were lower than in the animals
receiving cisplatin alone [37]. The present study did not
find any significant change in the renal tissue MPO values
in the CP and CP+NAC groups compared to the CONT
group.
Overall, there was no study found in the literature
showing that NAC alone has a direct effect on MPO levels,
but increased MPO values were observed after NAC
administration in the present study. The present study also
showed that neutrophil activation, and thus tissue MPO
levels, which are believed to be suppressed by cisplatin
administration, remain unchanged by NAC administered
together with cisplatin.
This study detected a numerical but statistically
nonsignificant decrease in the tissue NF-kB levels of
the animals receiving cisplatin. These results seem to
be consistent with the results of similar studies in the
literature [38,39]. This might be because of the changes in
the animal species used, cisplatin dose, and/or the timing
of euthanasia. That being said, the decreased NF-kB levels
in this study might be explained by the fact that cisplatin
causes NF-kB inhibition by binding the “kB” regions,
which are the NF-kB DNA binding regions, and, as a
result, leads to an increase in the apoptosis and necrosis
sensitivity of the tumor cells [40]. In the end, it can be
thought that early NF-kB increase due to tissue damage
during cisplatin treatment may cause negative feedback
as it is not possible to bind to the “cisplatin-blocked kB”
regions on the DNA and thereby reduce its own level by
the time of euthanasia. Additionally, in another study, it
was specified that NF-kB, which was initially activated by
SOR under modest conditions, might be inhibited by SOR
to sustain vitality under severe conditions triggering cell
death [41].
Examining the effects of NAC on the DNA-binding
activity of NF-kB in different cell lines, Liu et al. [42]
showed that NAC induces cytoplasmic inhibitor of
nuclear factor kappa-B kinase- and phosphatidylinositol 3
kinase-mediated p65 subunit phosphorylation and NF-kB
activation in a dose-dependent manner. As they did not
obtain the same results with different antioxidants such as
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vitamin C or tetramethyl thiourea, they suggested that this
effect does not depend on the antioxidant characteristic of
NAC. According to these results, it is possible to say that
numerically increased NF-kB levels in rats that received
NAC alone in this study might be because of the NACmediated NF-kB activation. Similarly, the increase in
MPO might also be associated with this pathway, and the
significant increase observed in MPO levels of the NAC250 group might be due to induction of NOX-2 activation
by NF-kB [41].
It has also been reported that the inflammatory effects of
cisplatin might also be mediated by the damage-associated
molecular pattern (DAMP), which develops secondary to
intracellular damage and causes chemokine and cytokine
release [16]. Therefore, as a well-known member of the
DAMP family and also known for contributing to sterile
inflammation, HMGB-1 [43] might be contributing to the
toxic status seen during cisplatin treatment.
However, there is no generally accepted correlation
between HMGB-1 and cisplatin cytotoxicity [44]. Park
et al. [45] suggested that poly(ADP-ribose) polymerase
1-dependent HMGB-1 release increases due to oxidative
stress seen in the renal proximal tubule cells after highdose cisplatin administration, and this contributes to the
cisplatin-induced inflammation. While the presence of
oxidative stress was demonstrated by increased TOS and
decreased TAS levels in the present study, such an increase
was not observed in HMGB-1 levels.
The present study found that HMGB-1 concentration
in the renal tissue was increased in the NAC-250 group
compared to the control, and it was significantly higher in
the cisplatin groups (CP and CP+NAC) than the NAC-250
group and numerically lower than in the control group.
However, no study was found in the literature on the effect

of NAC against HMGB-1 levels changing after cisplatin
administration.
That being said, there are studies showing that HMGB1 increase can be reversed by NAC expression in support
of this increase being mediated by oxidative stress [46,47].
Yang et al. [47] demonstrated that HMGB-1 increase due
to SOR induced by high glucose concentrations in the
human proximal tubule epithelial cell line can be reversed
by NAC.
However, the fact that the significant increases
in tissue MPO and HMGB-1 levels in the NAC-250
group accompany damage that was demonstrated
histopathologically but not biochemically suggests that
NAC causes inflammation-mediated tissue damage, albeit
limited. Known to have very minimal toxic effects, NAC
was not studied in this study for this effect. Future studies
are needed to explain this phenomenon.
While the changes in the urine/blood urea nitrogen
and creatinine levels seen with NAC administration after
cisplatin did not reach the levels of the control group,
certain histopathological and biochemical improvement
was observed. However, a satisfactory assessment of
the inflammatory status could not be performed due to
possible interactions between cisplatin and the parameters
believed to reflect the extent of the inflammation in the
renal tissue. Nonetheless, when the results of this study are
assessed histologically and in terms of renal function tests,
it would be more appropriate to use NAC for long-term
treatments at low doses to reduce the cisplatin-induced
tissue damage.
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